BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 27283742)

  • 1. Activation of Peroxisome Proliferator-Activated Receptor-δ as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis.
    Hytönen J; Leppänen O; Braesen JH; Schunck WH; Mueller D; Jung F; Mrowietz C; Jastroch M; von Bergwelt-Baildon M; Kappert K; Heuser A; Drenckhahn JD; Pieske B; Thierfelder L; Ylä-Herttuala S; Blaschke F
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1534-48. PubMed ID: 27283742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.
    Torella D; Curcio A; Gasparri C; Galuppo V; De Serio D; Surace FC; Cavaliere AL; Leone A; Coppola C; Ellison GM; Indolfi C
    Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2935-43. PubMed ID: 17293493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-Activated Peroxisome Proliferator-Activated Receptor δ Attenuates Vascular Oxidative Stress by Inhibiting Thrombospondin-1 Expression.
    Ahn MY; Ham SA; Yoo T; Lee WJ; Hwang JS; Paek KS; Lim DS; Han SG; Lee CH; Seo HG
    J Vasc Res; 2018; 55(2):75-86. PubMed ID: 29408825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Eluting Stent Targeting Sp-1-Attenuated Restenosis by Engaging YAP-Mediated Vascular Smooth Muscle Cell Phenotypic Modulation.
    Huang C; Zhao J; Zhu Y
    J Am Heart Assoc; 2020 Jan; 9(1):e014103. PubMed ID: 31880978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting AGGF1 (angiogenic factor with G patch and FHA domains 1) for Blocking Neointimal Formation After Vascular Injury.
    Yao Y; Hu Z; Ye J; Hu C; Song Q; Da X; Yu Y; Li H; Xu C; Chen Q; Wang QK
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28649088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Tauroursodeoxycholic Acid on Dedifferentiation of Vascular Smooth Muscle Cells by Modulation of Endoplasmic Reticulum Stress and as an Oral Drug Inhibiting In-Stent Restenosis.
    Luo H; Zhou C; Chi J; Pan S; Lin H; Gao F; Ni T; Meng L; Zhang J; Jiang C; Ji Z; Lv H; Guo H
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):25-33. PubMed ID: 30663009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of curcumin for preventing restenosis in a hypercholesterolemic rabbit iliac artery stent model.
    Jang HS; Nam HY; Kim JM; Hahm DH; Nam SH; Kim KL; Joo JR; Suh W; Park JS; Kim DK; Gwon HC
    Catheter Cardiovasc Interv; 2009 Nov; 74(6):881-8. PubMed ID: 19496118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan.
    Segev A; Nili N; Osherov AB; Qiang B; Wong AJ; Pillarisetti S; Strauss BH
    EuroIntervention; 2010 May; 6(1):134-40. PubMed ID: 20542809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvacrol inhibits atherosclerotic neointima formation by downregulating reactive oxygen species production in vascular smooth muscle cells.
    Lee KP; Sudjarwo GW; Jung SH; Lee D; Lee DY; Lee GB; Baek S; Kim DY; Lee HM; Kim B; Kwon SC; Won KJ
    Atherosclerosis; 2015 Jun; 240(2):367-73. PubMed ID: 25875388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast Growth Factor 12 Is a Novel Regulator of Vascular Smooth Muscle Cell Plasticity and Fate.
    Song SH; Kim K; Jo EK; Kim YW; Kwon JS; Bae SS; Sung JH; Park SG; Kim JT; Suh W
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1928-36. PubMed ID: 27470512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition.
    Wu BJ; Li Y; Ong KL; Sun Y; Shrestha S; Hou L; Johns D; Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2333-2341. PubMed ID: 29025709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting stent specifically designed to target vascular smooth muscle cell phenotypic modulation attenuated restenosis through the YAP pathway.
    Huang C; Zhang W; Zhu Y
    Am J Physiol Heart Circ Physiol; 2019 Sep; 317(3):H541-H551. PubMed ID: 31298560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
    Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
    FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy.
    Curcio A; Torella D; Indolfi C
    Circ J; 2011; 75(6):1287-96. PubMed ID: 21532177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble epoxide hydrolase is involved in the development of atherosclerosis and arterial neointima formation by regulating smooth muscle cell migration.
    Wang Q; Huo L; He J; Ding W; Su H; Tian D; Welch C; Hammock BD; Ai D; Zhu Y
    Am J Physiol Heart Circ Physiol; 2015 Dec; 309(11):H1894-903. PubMed ID: 26453326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of neointimal hyperplasia in the rat carotid artery injury model by a HMGB1 inhibitor.
    Chen J; Zhang J; Xu L; Xu C; Chen S; Yang J; Jiang H
    Atherosclerosis; 2012 Oct; 224(2):332-9. PubMed ID: 22857898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digoxin inhibits PDGF-BB-induced VSMC proliferation and migration through an increase in ILK signaling and attenuates neointima formation following carotid injury.
    Yan G; Wang Q; Hu S; Wang D; Qiao Y; Ma G; Tang C; Gu Y
    Int J Mol Med; 2015 Oct; 36(4):1001-11. PubMed ID: 26311435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR delta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle.
    Lim HJ; Lee S; Park JH; Lee KS; Choi HE; Chung KS; Lee HH; Park HY
    Atherosclerosis; 2009 Feb; 202(2):446-54. PubMed ID: 18585719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation.
    Duran-Prado M; Morell M; Delgado-Maroto V; Castaño JP; Aneiros-Fernandez J; de Lecea L; Culler MD; Hernandez-Cortes P; O'Valle F; Delgado M
    Circ Res; 2013 May; 112(11):1444-55. PubMed ID: 23595952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirtuin 1 Mediates the Actions of Peroxisome Proliferator-Activated Receptor δ on the Oxidized Low-Density Lipoprotein-Triggered Migration and Proliferation of Vascular Smooth Muscle Cells.
    Hwang JS; Ham SA; Yoo T; Lee WJ; Paek KS; Lee CH; Seo HG
    Mol Pharmacol; 2016 Nov; 90(5):522-529. PubMed ID: 27573670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.